Payment overview · 2025
General Payments
$776.20
37 reported records · 12 companies
Healthcare provider profile · identity verified
Thuc Ba Tu, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · LONG BEACH, CA · NPI 1699979229
Verified facts
What the public records show
CMS Open Payments records show Thuc Ba Tu, MD received $776.20 in general payments during 2025 across 37 reported records.
Amgen Inc. accounted for 26.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia, Ozempic.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Prolia by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $203.05 | 26.2% | 11 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $183.16 | 23.6% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $85.24 | 11.0% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $70.25 | 9.1% | 3 | 2025 |
| Calliditas Therapeutics US Inc. | Unresolved — no canonical attribution shown | $62.88 | 8.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $31.47 | 4.0% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $30.24 | 3.9% | 2 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.71 | 3.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.18 | 3.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.29 | 3.1% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $20.82 | 2.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $13.91 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $776.20 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $183.16 | 9 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $99.41 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $85.00 | 5 | 2025 |
Source payment records
|
|||||
| TARPEYO Normalized: tarpeyo |
Drug | Calliditas Therapeutics US Inc. | $62.88 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $60.44 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $57.67 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $51.25 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $51.25 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $44.18 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $31.47 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $31.47 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $30.24 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $27.57 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $25.71 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $24.29 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $20.82 | 1 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $18.64 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $13.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 120 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 118 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
19 | 12 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
118 | 18 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
120 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
120 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
89 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 420 | 96 |
| Metoprolol Succinate | Metoprolol Succinate | 380 | 79 |
| Amlodipine Besylate | Amlodipine Besylate | 371 | 90 |
| Atorvastatin Calcium | Atorvastatin Calcium | 341 | 90 |
| Farxiga | Dapagliflozin Propanediol | 269 | 51 |
| Gabapentin | Gabapentin | 259 | 60 |
| Metformin Hcl | Metformin Hcl | 255 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 248 | 72 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 230 | 69 |
| Lovastatin | Lovastatin | 228 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 208 | 53 |
| Mirtazapine | Mirtazapine | 179 | 34 |
| Hydralazine Hcl | Hydralazine Hcl | 171 | 33 |
| Famotidine | Famotidine | 166 | 45 |
| Simvastatin | Simvastatin | 166 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 163 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 151 | 34 |
| Vascepa | Icosapent Ethyl | 150 | 33 |
| Montelukast Sodium | Montelukast Sodium | 148 | 39 |
| Sevelamer Carbonate | Sevelamer Carbonate | 146 | 36 |
| Levothyroxine Sodium | Levothyroxine Sodium | 138 | 29 |
| Trazodone Hcl | Trazodone Hcl | 138 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 136 | 33 |
| Nifedipine Er | Nifedipine | 133 | 23 |
| Donepezil Hcl | Donepezil Hcl | 129 | 35 |
| Jardiance | Empagliflozin | 120 | 27 |
| Kerendia | Finerenone | 118 | 18 |
| Baclofen | Baclofen | 117 | 22 |
| Omeprazole | Omeprazole | 115 | 25 |
| Carvedilol | Carvedilol | 114 | 20 |
| Alendronate Sodium | Alendronate Sodium | 112 | 30 |
| Lisinopril | Lisinopril | 103 | 19 |
| Furosemide | Furosemide | 100 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 100 | 28 |
| Allopurinol | Allopurinol | 99 | 30 |
| Icosapent Ethyl | Icosapent Ethyl | 93 | 29 |
| Januvia | Sitagliptin Phosphate | 93 | 14 |
| Azithromycin | Azithromycin | 92 | 69 |
| Clonidine Hcl | Clonidine Hcl | 91 | 23 |
| Clobetasol Propionate | Clobetasol Propionate | 90 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 90 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 90 | 32 |
| Finasteride | Finasteride | 90 | 24 |
| Eliquis | Apixaban | 89 | 15 |
| Colchicine | Colchicine | 86 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 86 | 24 |
| Ibuprofen | Ibuprofen | 85 | 33 |
| Megestrol Acetate | Megestrol Acetate | 85 | 21 |
| Memantine Hcl | Memantine Hcl | 85 | 16 |
| Tradjenta | Linagliptin | 85 | 12 |
| Glipizide | Glipizide | 83 | 17 |
| Loperamide | Loperamide Hcl | 83 | 42 |
| Levetiracetam | Levetiracetam | 82 | suppressed |
| Celecoxib | Celecoxib | 81 | 26 |
| Ezetimibe | Ezetimibe | 76 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 74 | 19 |
| Dapagliflozin | Dapagliflozin Propanediol | 72 | 26 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 67 | 20 |
| Ventolin Hfa | Albuterol Sulfate | 67 | 17 |
| Benazepril Hcl | Benazepril Hcl | 65 | 12 |
| Mupirocin | Mupirocin | 64 | 21 |
| Ketoconazole | Ketoconazole | 62 | 14 |
| Potassium Chloride | Potassium Chloride | 61 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 23 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 58 | 14 |
| Prednisone | Prednisone | 58 | 34 |
| Doxycycline Hyclate | Doxycycline Hyclate | 57 | 39 |
| Ibandronate Sodium | Ibandronate Sodium | 56 | 14 |
| Lidocaine | Lidocaine | 56 | 12 |
| Dexlansoprazole Dr | Dexlansoprazole | 55 | 15 |
| Velphoro | Sucroferric Oxyhydroxide | 55 | 12 |
| Meclizine Hcl | Meclizine Hcl | 51 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | suppressed |
| Bumetanide | Bumetanide | 48 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 48 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | suppressed |
| Restasis | Cyclosporine | 45 | 13 |
| Calcium Acetate | Calcium Acetate | 44 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 43 | 11 |
| Memantine Hcl Er | Memantine Hcl | 43 | suppressed |
| Procto-Med Hc | Hydrocortisone | 43 | 15 |
| Cyclosporine | Cyclosporine | 42 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 41 | 31 |
| Midodrine Hcl | Midodrine Hcl | 41 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 32 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 40 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 40 | suppressed |
| Pure Comfort Alcohol Pad | Alcohol Antiseptic Pads | 40 | 14 |
| Nitroglycerin | Nitroglycerin | 39 | 14 |
| Metronidazole | Metronidazole | 38 | 21 |
| Pregabalin | Pregabalin | 38 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 37 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 37 | suppressed |
| Ozempic | Semaglutide | 36 | suppressed |
| Rybelsus | Semaglutide | 34 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 34 | 15 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 33 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 33 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 32 | suppressed |
| Febuxostat | Febuxostat | 32 | suppressed |
| Latanoprost | Latanoprost | 32 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 32 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | suppressed |
| Levofloxacin | Levofloxacin | 31 | 25 |
| Renvela | Sevelamer Carbonate | 31 | suppressed |
| Acarbose | Acarbose | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Hydrocortisone | Hydrocortisone | 29 | 12 |
| Telmisartan | Telmisartan | 29 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 26 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 26 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 15 |
| Teflaro | Ceftaroline Fosamil Acetate | 25 | suppressed |
| Dutasteride | Dutasteride | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Alogliptin | Alogliptin Benzoate | 23 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 23 | suppressed |
| Ramipril | Ramipril | 23 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Xphozah | Tenapanor Hcl | 23 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 22 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 16 |
| Cinacalcet Hcl | Cinacalcet Hcl | 22 | suppressed |
| Lactulose | Lactulose | 22 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Lanthanum Carbonate | Lanthanum Carbonate | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | 13 |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 19 | 14 |
| Prolia | Denosumab | 19 | 12 |
| Spiriva Handihaler | Tiotropium Bromide | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 17 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 17 | suppressed |
| Ramelteon | Ramelteon | 17 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Mitigare | Colchicine | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Felodipine Er | Felodipine | 15 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 15 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | suppressed |
| Minoxidil | Minoxidil | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 14 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 13 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Phenytoin | Phenytoin | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Meloxicam | Meloxicam | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $776.20 · 37 records | Amgen Inc. | FREESTYLE LIBRE 3, FUROSCIX, GVOKE HYPOPEN, IBSRELA, JARDIANCE, KRYSTEXXA, Kerendia, MOUNJARO, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, REPATHA, TARPEYO, TAVNEOS, Wegovy, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error